ArticleVaccines2021
BNT162b2 mRNA COVID-19 Vaccine Effectiveness in the Prevention of SARS-CoV-2 Infection and Symptomatic Disease in Five-Month Follow-Up: A Retrospective Cohort Study.
Article in Vaccines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- COVID-19 vaccination hesitancy among Italian parents: A systematic review and meta-analysis.Human vaccines & immunotherapeutics · 2023Pooled it
- Predicting vaccine effectiveness against severe COVID-19 over time and against variants: a meta-analysis.Nature communications · 2023Pooled it
- Vaccine efficacy against SARS-CoV-2 for Pfizer BioNTech, Moderna, and AstraZeneca vaccines: a systematic review.Frontiers in public health · 2023Pooled it
- The role of hospitals in monitoring the emergency: the experience of "Sentinel network" of the Italian Federation of Health Trusts.BMC health services research · 2026Article
- COVID-19 vaccination remains essential for healthcare professionals: clinical evidence from a Polish cross-sectional study.Frontiers in public health · 2026Article
- COVID-19 vaccines are effective at preventing symptomatic and severe infection among healthcare workers: A clinical review.Vaccine: X · 2024Review
- Consequences of COVID-19 Vaccine Hesitancy Among Healthcare Providers During the First 10 Months of Vaccine Availability: Scoping Review.The Canadian journal of nursing research = Revue canadienne de recherche en sciences infirmieres · 2024Article
- Immunogenicity after vaccination of COVID-19 vaccines in patients with cancer: a prospective, single center, observational study.International journal of clinical oncology · 2024Observational
- Determinants of compliance to influenza and COVID-19 vaccination in a cohort of solid organ transplant patients in Puglia, Southern Italy (2017-2022).Human vaccines & immunotherapeutics · 2023Article
- A panoramic view of hospitalized young children in the metropolitan area of the valley of Mexico during COVID-19.IJID regions · 2023Article
- Adolescents' Opinions on COVID-19 Vaccine Hesitancy: Hints toward Enhancing Pandemic Preparedness in the Future.Vaccines · 2023Article
- COVID-19 vaccine acceptance and its determinants among residents of Ambo Town, West Shewa, Oromia Region, Ethiopia: cross-sectional survey.Therapeutic advances in vaccines and immunotherapy · 2023Article
- COVID-19 in the Arab countries: Three-year study.F1000Research · 2023Review
- Ultra-rapid rollout vaccination with BNT162b2 to reduce SARS-CoV-2 infections in the general population.iScience · 2022Article
- The effectiveness of mRNA vaccines to prevent SARS-CoV-2 infection and hospitalisation for COVID-19 according to the time elapsed since their administration in health professionals in the Valencian Autonomous Community (Spain).Preventive medicine · 2022Article
- Article
- COVID-19 Severity and Mortality after Vaccination against SARS-CoV-2 in Central Greece.Journal of personalized medicine · 2022Article
- SARS-CoV-2 mRNA Vaccine Effectiveness in Health Care Workers by Dosing Interval and Time Since Vaccination: Test-Negative Design, British Columbia, Canada.Open forum infectious diseases · 2022Article
- Estimation of Real-World Vaccination Effectiveness of mRNA COVID-19 Vaccines against Delta and Omicron Variants in Japan.Vaccines · 2022Article
- COVID-19 Infection in Children and Infants: Current Status on Therapies and Vaccines.Children (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To combat the COVID-19 pandemic, a mass vaccination campaign was initiated in Italy on 27 December 2020. The vaccine available to immunize Italian healthcare workers (HCWs) was the BNT162b2 mRNA COVID-19 vaccine (Comirnaty). This study evaluated the effectiveness of the vaccine against documented SARS-CoV-2 infection and symptomatic diseases in the medium- to long-term. HCWs at Bari Policlinico University-Hospital (Italy) who completed the vaccination schedule were matched with HCWs who had refused vaccination; the two groups were followed-up for 5 months (January-May 2021). Vaccine effectiveness (VE) against infection was 97.7% (95.4-99.0%) at 14-34 days after the first dose, and 94.8% (87.0-97.8%), 83.0% (65.0-92.0%), and 81.0% (42.0-94.0%) at 14-41, 42-69, and >69 days, respectively, after the second dose. The estimated VE for documented symptomatic disease was 99.2% (96.4-99.8%) at 14-34 days after the first dose and 97.2% (90.3-99.2%), 85.0% (63.0-94.2%), and 88.0% (42.0-97.6%) at 14-41, 42-69, and >69 days, respectively, after the second dose. Efforts to increase vaccination rates should be strengthened, including mandatory vaccination for HCWs and greater incentives to increase vaccine acceptance by the general population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.